Private Placement

With its latest $200M notes offering, Superior Energy isn't just buying another company; it's making a calculated bet on stability in a volatile market.

As Helius Minerals pushes to acquire Brazil's legendary Serra Pelada mine, a rival's legal victory resurrects old claims. But what does the ruling truly mean?

A $170M recapitalization of Lone Peak Dental Group isn't just finance. It's a test of whether private credit can expand vital care for underserved kids.

iPower Inc. secured $2M to fund a pivot into AI, but a closer look reveals a company battling financial headwinds while making a risky bet on its future.

With record sales and strategic deals, this French innovator is proving that green cement isn't just possible, it's profitable and scaling fast.

Despite high debt, GardaWorld's new half-billion-dollar financing was heavily oversubscribed. It's a massive vote of confidence in its tech-driven M&A strategy.

Peruvian mining giant Minsur just bought a 13.8% stake in a small Canadian explorer. But the real story is in the fine print: a clear path to the prize.

With a fresh $7.5M, event tech firm TEN Holdings is at a crossroads. Can this capital injection overcome deep financial woes and fund a digital future?

The media giant leverages new debt for a strategic acquisition while buying back preferred stock at a steep discount, a bold bet on local broadcast's future.

FreeCast secures a crucial $23.7M funding round to fuel its streaming platform ambitions, but can this capital build a sustainable digital backbone on a shaky financial foundation?

After a brutal $4.9M loss driven by product obsolescence, the avionics firm is betting its future on major defense contracts. But can it navigate tight cash?

Premium Income Corp. raises $70M in a bold overnight offering. What does this move, backed by Canada's big banks, mean for your portfolio and market stability?

With a fresh $30M from a long-term investor, Mitesco is shedding its past to chase high-growth acquisitions in the booming data center and AI sectors.

The tech firm's new funding addresses urgent debt amid Nasdaq delisting threats, revealing a complex financial maneuver to keep its K-culture dreams alive.

NurExone's modest C$628k funding isn't a sign of weakness, but a masterclass in biotech survival. It's a strategic play in a cautious market.

Jacksonville's Duos Technologies gains major investor visibility with its Russell 2000 inclusion, a key milestone validating its strategic AI infrastructure shift.

From staid SaaS to a Bitcoin Cash treasury, mF International has remade itself. We look beneath the surface of its radical reinvention and ask: is this genius or a gamble?

FibroBiologics secures $3M with a path to $9M, fueling its promising cell therapy pipeline. But is this a strategic masterstroke or a necessary risk?

4DMT secures a complex $200M credit facility, choosing strategic debt over equity. We dissect the deal and what it signals for late-stage biotech financing.

A shareholder revolt at Solmate Infrastructure exposes deep governance rifts, as a board's re-election hinges on votes from a controversial share deal.